How severe are the side effects of Ivosidenib?

Some side effects usually do not require medical treatment and may resolve on their own as your body gradually adjusts to the medication.

How severe are the side effects of Ivosidenib?

Your doctor may also provide you with strategies to prevent or alleviate certain side effects. If you experience any of the following side effects—and they persist, cause significant discomfort, or raise any concerns for you—please consult your doctor:

Common side effects include chapped or dry lips, decreased appetite, diarrhea, difficulty swallowing, nausea, and vomiting.

Other side effects not listed here may also occur in some patients. If you notice any unusual reactions, please contact your doctor promptly.

What drugs may interact with Ivosidenib?

Do not take this medication concomitantly with the following drugs: dronedarone, pimozide, or thioridazine.

Ivosidenib may also interact with numerous other medications, including:Certain antiviral drugs used to treat HIV or hepatitis B/C;Certain antifungal agents (e.g., fluconazole, itraconazole, ketoconazole);Certain antiarrhythmic drugs (e.g., amiodarone, encainide, flecainide, propafenone, quinidine);Certain antiepileptic drugs (e.g., carbamazepine, phenobarbital, phenytoin);Estrogen- and progestin-containing medications;Grapefruit juice;Other medications that may affect heart rhythm;Rifampin; andSt. John’s wort.

This list may not include all possible drug interactions. Please provide your healthcare provider with a complete list of all prescription and over-the-counter medications, herbal products, and dietary supplements you are currently using. Additionally, inform them if you smoke, consume alcohol, or use illicit drugs, as these factors may also interact with your medication.

Monitoring requirements for Ivosidenib

Before initiating treatment and at regular intervals during therapy, blood cell counts and blood chemistry should be evaluated as follows:

1. At least once weekly during the first month of treatment;

2. Every two weeks during the second month;

3. Monthly thereafter throughout the course of treatment.

4. Serum creatine phosphokinase (CPK) levels should be monitored: 4. Once weekly during the first month of treatment.

Electrocardiogram (ECG) monitoring:

1. At least once weekly within the first 3 weeks of treatment;

2. At least once monthly thereafter during treatment;

3. Any abnormalities detected should be addressed promptly.